Authoritative guidelines for oncology professionals for the treatment of all major malignancies, and for their detection, prevention, risk reduction, and associated supportive care. From The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of leading cancer centers in the U.S.
Patient versions of authoritative NCCN guidelines for the treatment of nine of the most common cancer types. From The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of leading cancer centers in the U.S.
Authoritative clinical practice guidelines for oncology professionals, including treatment and supportive care, and assays and predictive markers. From the American Society of Clinical Oncology whose guidelines, along with those of NCCN, determine current oncology practice.
Evidence-based systematic reviews in cancer care and research, with evidence summaries for both healthcare providers and the public. From Cancer Care ontario.
A message campaign that provides cancer survivors with an evidence-based, but user-friendly, approach detailing eight domains of a critical health promotion program. [2013]
A collaborative wiki created by oncologists as a knowledge base for oncotherapy (chemotherapy, biological, and endocrine) drugs and regimens subcategorized by cancer type, providing dosing, schedule and level of confirming evidence.
Assesses the overall reporting quality of oncology RCTs according to recognized CONSORT criteria, finding that despite significant improvments, many items remain very poorly reported and may conceal important problems in trial design or conduct. [2012]
Review that finds poor reporting of adverse events (AEs) in oncology RCTs, which was not appreciably better among articles published in high impact factor journals. [2013]
Evidence-based practice guidelines on the treatment of adult and pediatric brain tumor patients, from the American Brain Tumor Association (ABTA) and the American Association of Neuroscience Nurses (AANN).
Evidence-based critical review of claimed anticancer activities of metformin and Vitamin D including Vitamin D randomized trials, and highlighting the limitations of observational studies. From ASCO (American Society of Clinical Oncology. [2014]
Evidence-based practice guidelines for interventional therapies in the management of iintractable cancer pain not amenable to standard oral or parenteral analgesics. [2015]
Systematic review of randomized controlled trials, systematic reviews, meta-analyses, and prospective cohort studies assessing the current evidence base on the benefits and risks of complementary therapies in patients with lung cancer. [2013]
Evidence-based clinical practice guidelines for the use of complementary and/or integrative therapies in breast cancer patients during and beyond cancer treatment to manage symptoms, prevent toxicities, and improve quality of life; Journal of the National Cancer Institute Monograph. [2014]
Summarizes the epidemiological evidence for an association between diabetes and various cancers, and explores the pathophysiological mechanisms potentially involved in promoting carcinogenesis in diabetes and the impact of different anti-diabetic therapies on cancer risk. [2015]
Discusses and contrasts two perspectives on the evidence for PSA screening from opposing camps on this issue: Dr Timothy Wilt on the hazards of PSA screening and Dr Peter Scardino on the merits of tailored PSA screening. From an educational session at the 2013 ASCO annual meeting on this topic. [2014]
Describes interactive approaches for accelerating dissemination and implementation of evidence-based interventions in oncology, illustrated using examples from obesity prevention and tobacco control. [2014]
Critical appraisal of the strength and quality of the evidence regarding the safety and efficacy of pharmacologic and nonpharmacologic interventions to ameliorate cancer-related fatigue (CRF) during and following cancer and its treatment, and at the end of life. [2014]
A systematic review based on the Institute of Medicine’s guideline development process to identify randomized controlled trials on the efficacy of integrative therapies for supportive care in patients receiving breast cancer treatment. [2014]
Appreciation of the work and goals of the National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (NIH) in assessing efficacy and safety of interventions in integrative oncology. [2014]
Evidence-based review the literature on the medical use and safety of marijuana and cannabinoid pharmaceuticals, with emphasis on indications relevant to oncology. [2015]
Evidence-based review from MD Anderson Cancer Center of mind-body techniques such as meditation, yoga, tai chi, and qigong for improvements in different aspects of the quality of life of cancer patients. [2015]
Evidence-based summary of research results stemming from the integration of complementary therapies with mainstream oncology care when using nonpharmacologic modalitiesto reduce symptom burden and improve quality of life in cancer patients. From the Integrative Medicine Service at Memorial Sloan Kettering Cancer Center. [2015]
Ten recommendations to help physicians in counseling their young cancer patients interested in fertility preservation, from a workshop of content experts on the topic of “cancer and fertility preservation” held in Genova in April 2015. [2016]
Review of existing evidence for the use of complementary and integrative interventions to prevent or treat cancer-related cognitive changes and discussion of the rationale for current and future research. [2015]
Prospective evaluation of the incidence, time of occurrence, clinical correlates, and response to heart failure therapy of anthracycline-related cardiotoxicity in the oncology setting. [2015]
Critical review of the best evidence to date for the treatment of hepatocellular carcinoma (HCC), both local therapies and pharmacological interventions. [2015]
Reflections on, and an editorial call for, a transition of onco-cardiology from an expert-based into an evidence-based discipline. Article in Journal of Thoracic Disease [2015]
Critical evaluation of outcome in clinical trials performed in postmenopausal patients with advanced breast cancer treated with various endocrine regimens, including letrozole, anastrozole, exemestane and fulvestrant. [2016]